News

In its response to the European Commission’s public consultation on the prescription drug information, the European Federation of Pharmaceutical Industries and Associations (EFPIA) emphasized the need for a

The results demonstrated that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14).

This approval – the third for pemetrexed in Europe – follows an initial positive opinion issued by the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human

The Attract-1 trial is a randomized, double-blind, placebo-controlled, multicentre Phase III trial being conducted across the US, EU and other territories. With 1200 patients, it will be amongst

This is the second patent application of 2008 which was made pursuant to Kraig’s sponsored research program at the University of Notre Dame and which is subject to

At the second closing, the company sold 2,195 shares of series A convertible preferred stock for $1,000 per share, or gross proceeds of approximately $2.2 million. At the

The Endolase RFT Root Canal Therapy System and the Waterlase MD laser system are now available through the company’s North American distributor Henry Schein Dental, the Biolase direct

The grant of the European patent is expected in several weeks. Other patents related to the Antisenilin antibodies have been granted in Japan, China and elsewhere. Patent applications

There are currently over 20 marketed products using peptides protected under the patent including such cosmeceutical brands as Fusion Beauty, Smashbox, Isomers, and B Kamins. Numerous additional product